Why gC2, gD2, and gE2? The trivalent vaccine rationale
Last updated:
Several leading HSV-2 vaccine candidates combine three viral surface proteins — gC2, gD2, and gE2 — to do two jobs at once: block the virus from entering cells and disable two of the tricks it uses to evade the immune system. The rationale is well supported by animal data; whether it protects people is still being tested in an early-stage (Phase 1) human trial of the candidate BNT163.
The short answer
Herpes simplex virus (HSV) is studded with proteins on its outer surface. Some of the most advanced experimental vaccines, including several based on mRNA, use a “trivalent” design — one that targets three of these HSV-2 surface proteins at the same time: gC2, gD2, and gE2. (A glycoprotein is a protein with sugar molecules attached; the “2” marks each as the HSV-2 version. The virus that causes most genital herpes is HSV-2, while its close relative HSV-1 more often causes oral cold sores.) The logic behind picking these three is to accomplish two goals simultaneously: block the virus from entering cells, and disable two of the tools the virus uses to evade the immune system. [S6][S3]
gD2 — the entry target (and why it wasn’t enough alone)
Glycoprotein D (gD) is a surface protein that helps HSV enter human cells. Antibodies directed against gD can interfere with that step, which made it the natural first target for a vaccine. It was, in fact, the only active ingredient — the sole antigen — in the Herpevac vaccine tested in a large Phase 3 efficacy trial (an in-human trial designed to measure whether a vaccine actually prevents disease). In that trial, the gD-only vaccine did not protect against HSV-2: overall efficacy against genital herpes disease was 20% (a result whose confidence interval crossed zero, meaning no protective effect could be established), and no efficacy against HSV-2 infection was observed. Blocking entry alone left the virus’s immune-evasion machinery completely untouched. [S5]
gC2 and gE2 — stripping away immune evasion
The other two proteins were chosen precisely because the virus uses them to hide from the immune system.
Glycoprotein C (gC) binds a component of complement — a cascade of blood proteins that works alongside antibodies to help destroy pathogens — and by doing so it blunts that defense. Glycoprotein E (gE), working as part of a complex with a partner protein called gI, acts as an antibody Fc receptor: an Fc receptor is a molecule that grabs antibodies by their “tail” end (the Fc region, the opposite end from the part that recognizes the target), so the antibodies can no longer properly flag the virus for destruction. Immunizing against gC2 and gE2 raises antibodies that block these two evasion functions, freeing the rest of the immune response to do its job. [S3][S6]
Why combine all three (trivalent)
The intended effect is additive. Antibodies against gD2 work to block the virus from entering cells, while antibodies against gC2 and gE2 work to disarm the virus’s defenses — so the immune system is attacking on more than one front at once. In animal studies, this played out as measurably better protection: in mice, the trivalent gC2/gD2/gE2 combination protected the dorsal root ganglia (the nerve clusters where HSV can establish long-term latent infection) in 97% of animals — 32 of 33 — compared with 82%, or 27 of 33, for gD2 alone. [S6]
Whose approach this is
The trivalent gC2/gD2/gE2 concept comes from the University of Pennsylvania (Perelman School of Medicine), in work led by Sita Awasthi and Harvey Friedman. [S6] The design was subsequently developed as an mRNA vaccine by BioNTech, encapsulated in lipid nanoparticles, and entered human testing as the clinical candidate BNT163, which is in a Phase 1 trial (registered as NCT05432583). [S3]
What this does and does not mean
The rationale for combining these three proteins is well grounded, and it is supported by data from animal studies. [S6] But animal data is preclinical evidence — results in mice, guinea pigs, or other animals, not yet in people. Whether the trivalent approach protects humans is still being tested in the early-stage (Phase 1) human trial of BNT163. [S3] A strong scientific rationale, and success in animals, is not the same thing as proven human efficacy; that question remains open until the human trials report their results.